ANSARY LABs provides genetic testing for detection of BRCA1 & BRCA2 genes
= Result are available within 48 hrs = Test is Rapid, Accurate and lnexpensive
The test detect human BRCA1 gene polymorphisms (mutations 185delAG, 4153delA, 5382insC,
3819del GTAAA, 3875delGTCT, 300T>G2080delA ) & human BRCA2 gene mutation (6174delT)
associated with inherited susceptibility to breast & ovarian cancers(1)
BRCAl and BRCA2 are human genes that produce tumor suppressor proteins, these proteins
help repair damaged DNA.
About 30% of cases with hereditary breast and ovarian cancer have mutations in the BRCAl
and BRCA2 genes. Women with a mutation in BRCAl gene have a 80-90% lifetime risk of
developing breast cancer, and 40-6S% chance of developing ovarian cancer
For BRCA2 gene mutation carrier, the estimated cumulative risk of breast cancer is 28% by
the age of 50 and 84% by the age of 70
The risk of ovarian cancer is 0.4% by the age of 50 and 27% by the age of 70 years (1)
Harmful mutations in BRCA1 and BRCA2 increase the risk of several cancers in addition to
breast and ovarian cancer. These include fallopian tube cancer and peritoneal cancer. Men
with BRCA2 mutations, and to a lesser extent BRCA1 mutations, are also at increased risk of
breast cancer and prostate cancer. Both men and women with harmful BRCA1 or BRCA2
mutations are at increased risk of pancreatic cancer (2)
Several options are available for managing cancer risk in individuals who have a known
harmful BRCA1 or BRCA2 mutation. These include enhanced screening, prophylactic (riskreducing) surgery, and chemoprevention (3)
Who should consider genetic testing for BRCAl and BRCA2 mutations ?
= Breast cancer diagnosed before age 50 years
= Multiple breast cancers in the family
= Cancer in both breasts in the same woman
= Cases of male breast cancer
= Both breast and ovarian cancers in either the same woman or the same family
= Two or more primary types of BRCA1- or BRCA2-related cancers in a single family member
(1) Marchina, E., Fontana, M.G., Speziani, M., Salvi, A., Ricca, G., Di Lorenzo, D. ... Barlati, S. (2010). BRCA1 and BRCA2
genetic test in high risk patients and families: counselling and management . Oncology Reports, 24, 1661-1667
(2) Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and
BRCA2 mutation carriers. JAMA 2017; 317(23):2402-2416
(3) Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation
carriers with cancer risk and mortality. JAMA 2010; 304(9):967-975